Potential Role of Bupropion Sustained Release for Cancer-Related Fatigue: a Double-Blind, Placebo-Controlled Study

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2018 Jun 26

PMID 29936730

Citations 9

Authors

Farzaneh Ashrafi

Sarah Mousavi

Mohammad Karimi

Affiliations

Soon will be listed here.

Abstract

Background: Cancer-related fatigue (CRF) is very common and can be experienced at all stages of disease and in survivors. CRF causes patients more distress than pain or nausea and vomiting. Different pharmacologic interventions have been evaluated for the management of CRF. The purpose of this study was to determine the efficacy of bupropion sustained release (SR) as a treatment for fatigue in patients with cancer. Methods: In this randomized, double-blind, placebo-controlled trial, patients with fatigue due to cancer were randomly assigned to either 150mg daily of bupropion SR or matching placebo. The primary endpoint was the changes in average daily fatigue from baseline to week 4 using the Functional Assessment of Chronic Illness-therapy- Fatigue (FACIT-F) questionnaire. Results: 40 patients were randomly assigned to treatment with bupropion SR or placebo (20 in each group). Analysis of covariance (ANCOVA) showed a significant improvement in fatigue and quality of life in the bupropion group compared to baseline (P=0.000). Secondary outcome, including depression, severity of fatigue and performance status didn’t show significant difference between groups. Generally, bupropion SR was tolerated well. Conclusion: Four weeks of 150 mg bupropion SR improve fatigue significantly in cancer patients. Bupropion has potential as an effective and safe pharmaceutical agent for treating CRF.

Citing Articles

5-EPIFAT trial protocol: a multi-center, randomized, placebo-controlled trial of the efficacy of pharmacotherapy for fatigue using methylphenidate, bupropion, ginseng, and amantadine in advanced cancer patients on active treatment.

Miladinia M, Jahangiri M, White S, Karimpourian H, Inno A, Chan S Trials. 2024; 25(1):230.

PMID: 38570861 PMC: 10988831. DOI: 10.1186/s13063-024-08078-w.

Antidepressants for the treatment of depression in people with cancer.

Vita G, Compri B, Matcham F, Barbui C, Ostuzzi G Cochrane Database Syst Rev. 2023; 3:CD011006.

PMID: 36999619 PMC: 10065046. DOI: 10.1002/14651858.CD011006.pub4.

Meta-Analysis of Pharmacological, Nutraceutical and Phytopharmaceutical Interventions for the Treatment of Cancer Related Fatigue.

Yennurajalingam S, Lu Z, De Moraes A, Tull N, Kubiak M, Geng Y Cancers (Basel). 2023; 15(1).

PMID: 36612088 PMC: 9817820. DOI: 10.3390/cancers15010091.

A New Approach to Understanding Cancer-Related Fatigue: Leveraging the 3P Model to Facilitate Risk Prediction and Clinical Care.

Sleight A, Crowder S, Skarbinski J, Coen P, Parker N, Hoogland A Cancers (Basel). 2022; 14(8).

PMID: 35454890 PMC: 9027717. DOI: 10.3390/cancers14081982.

Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial.

Salehifar E, Azimi S, Janbabai G, Zaboli E, Hendouei N, Saghafi F BMC Cancer. 2020; 20(1):158.

PMID: 32106832 PMC: 7045731. DOI: 10.1186/s12885-020-6618-9.

References

Cullum J, Wojciechowski A, Pelletier G, Simpson J . Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry. 2004; 49(2):139-44. DOI: 10.1177/070674370404900209. View

Fava M, Rush A, Thase M, Clayton A, Stahl S, Pradko J . 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005; 7(3):106-13. PMC: 1163271. DOI: 10.4088/pcc.v07n0305. View

Finnegan-John J, Molassiotis A, Richardson A, Ream E . A systematic review of complementary and alternative medicine interventions for the management of cancer-related fatigue. Integr Cancer Ther. 2013; 12(4):276-90. DOI: 10.1177/1534735413485816. View

Gerber L . Cancer-Related Fatigue: Persistent, Pervasive, and Problematic. Phys Med Rehabil Clin N Am. 2016; 28(1):65-88. DOI: 10.1016/j.pmr.2016.08.004. View

Pearson E, Morris M, di Stefano M, McKinstry C . Interventions for cancer-related fatigue: a scoping review. Eur J Cancer Care (Engl). 2016; 27(1). DOI: 10.1111/ecc.12516. View

Filler K, Saligan L . Defining cancer-related fatigue for biomarker discovery. Support Care Cancer. 2015; 24(1):5-7. PMC: 4670596. DOI: 10.1007/s00520-015-2965-5. View

Patel K, Allen S, Haque M, Angelescu I, Baumeister D, Tracy D . Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol. 2016; 6(2):99-144. PMC: 4837968. DOI: 10.1177/2045125316629071. View

Frison L, Pocock S . Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med. 1992; 11(13):1685-704. DOI: 10.1002/sim.4780111304. View

Saligan L, Olson K, Filler K, Larkin D, Cramp F, Yennurajalingam S . The biology of cancer-related fatigue: a review of the literature. Support Care Cancer. 2015; 23(8):2461-78. PMC: 4484308. DOI: 10.1007/s00520-015-2763-0. View

10.

Bower J . Cancer-related fatigue--mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014; 11(10):597-609. PMC: 4664449. DOI: 10.1038/nrclinonc.2014.127. View

11.

Bower J, Lamkin D . Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun. 2012; 30 Suppl:S48-57. PMC: 3978020. DOI: 10.1016/j.bbi.2012.06.011. View

12.

Zimmerman M, Martinez J, Young D, Chelminski I, Dalrymple K . Severity classification on the Hamilton Depression Rating Scale. J Affect Disord. 2013; 150(2):384-8. DOI: 10.1016/j.jad.2013.04.028. View

13.

Mustian K, Alfano C, Heckler C, Kleckner A, Kleckner I, Leach C . Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis. JAMA Oncol. 2017; 3(7):961-968. PMC: 5557289. DOI: 10.1001/jamaoncol.2016.6914. View

14.

Berger A, Mooney K, Alvarez-Perez A, Breitbart W, Carpenter K, Cella D . Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw. 2015; 13(8):1012-39. PMC: 5499710. DOI: 10.6004/jnccn.2015.0122. View

15.

Stahl S, Pradko J, Haight B, Modell J, Rockett C, Learned-Coughlin S . A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry. 2004; 6(4):159-166. PMC: 514842. DOI: 10.4088/pcc.v06n0403. View

16.

Minton O, Richardson A, Sharpe M, Hotopf M, Stone P . Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev. 2010; (7):CD006704. PMC: 11491194. DOI: 10.1002/14651858.CD006704.pub3. View

17.

Fatigoni S, Fumi G, Roila F . [Cancer-related fatigue]. Recenti Prog Med. 2015; 106(1):28-31. DOI: 10.1701/1740.18954. View

18.

Moss E, Simpson J, Pelletier G, Forsyth P . An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology. 2005; 15(3):259-67. DOI: 10.1002/pon.952. View